Mazdutide vs Retatrutide: Mechanism, Weight Loss, Approval & U.S. Status

The next generation of obesity medicines is moving beyond single-pathway GLP-1 drugs. Two names getting significant attention are mazdutide and retatrutide—two Lilly-related molecules that use glucagon signaling alongside GLP-1 activity, but take different approaches.

Mazdutide is a dual GLP-1/glucagon receptor agonist that has already reached approval in China. Retatrutide goes one step further, activating GLP-1, GIP, and glucagon receptors and remains investigational as clinical development continues.

Early results have made retatrutide particularly interesting because phase 2 data showed weight loss approaching 24% at the highest studied dose. Mazdutide has also produced meaningful results in phase 3 trials, although direct comparisons between the two drugs can be misleading because the studies involved different populations, trial phases, and designs.

So which one is more powerful? What does the added GIP receptor actually contribute? And, most importantly, can people in the United States access either medication?

Let's break down the evidence.

Mazdutide vs Retatrutide at a Glance

The simplest way to distinguish the two is by the receptors they activate.

Feature

Mazdutide

Retatrutide

GLP-1 receptor

Yes

Yes

GIP receptor

No

Yes

Glucagon receptor

Yes

Yes

Type

Dual agonist

Triple agonist

Developer

Lilly; licensed to Innovent in Greater China

Eli Lilly

China status

Approved for obesity

Not approved

U.S. status

Not FDA-approved

Investigational

Key clinical focus

Obesity and metabolic disease

Obesity, type 2 diabetes and other metabolic conditions

The distinction matters because the additional GIP pathway is one of the reasons retatrutide is being investigated as a potential next-generation obesity treatment.

What Is Mazdutide?

Mazdutide, also known as LY3305677, is a dual agonist that activates the GLP-1 and glucagon receptors.

Lilly licensed rights to develop and commercialize the molecule in Greater China to Innovent Biologics. It subsequently became an approved obesity treatment in China under the brand Sineipasy.

Its design combines two different biological effects.

What GLP-1 Does

GLP-1 receptor activation can:

• Reduce appetite

• Slow gastric emptying

• Increase glucose-dependent insulin secretion

• Improve blood-sugar control

• Contribute to weight loss through reduced food intake

What Glucagon Adds

Glucagon signaling works differently. It can increase energy expenditure and promote hepatic fatty-acid oxidation, potentially helping the body use stored energy more efficiently.

The idea behind mazdutide is therefore straightforward: combine appetite and glucose effects from GLP-1 with the metabolic effects associated with glucagon activation.

What Is Retatrutide?

Retatrutide, or LY3437943, is a triple agonist targeting GLP-1, GIP, and glucagon receptors.

Unlike mazdutide, it includes GIP receptor activity in addition to the GLP-1/glucagon combination.

Retatrutide is being developed directly by Eli Lilly and has advanced into phase 3 clinical trials. Its development program is evaluating the drug across several conditions, including obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and obstructive sleep apnea.

The major question is whether adding GIP to the GLP-1/glucagon combination can produce substantially greater benefits without creating an unacceptable increase in adverse effects.

How the Two Mechanisms Differ

Here's the fundamental difference:

Receptor

Mazdutide

Retatrutide

GLP-1

✓

✓

GIP

—

✓

Glucagon

✓

✓

Each pathway potentially contributes something different.

GLP-1 primarily supports appetite control, gastric-emptying effects, and glucose regulation.

GIP is another incretin pathway that can enhance glucose-dependent insulin secretion and may contribute to weight and metabolic effects when combined with other receptor agonists.

Glucagon can promote energy expenditure and fatty-acid oxidation while influencing hepatic metabolism.

Retatrutide therefore attempts to combine three complementary mechanisms in one molecule. The theory is that the effects could be additive or potentially synergistic.

However, receptor count alone does not guarantee a better medication. Greater pharmacological activity can also mean more side effects and a more complicated safety profile.

Does Retatrutide Cause More Weight Loss Than Mazdutide?

Early clinical results suggest that retatrutide may be more potent, but comparing the headline percentages directly is not scientifically fair.

Drug and dose

Trial

Phase

Duration

Mean weight loss

Retatrutide 12 mg

Jastreboff et al.

Phase 2

48 weeks

~24%

Retatrutide 8 mg

Jastreboff et al.

Phase 2

48 weeks

~22%

Mazdutide 9 mg

DREAMS-1

Phase 3

48 weeks

~14.4%

Mazdutide 6 mg

DREAMS-1

Phase 3

48 weeks

~12%

At first glance, the difference looks dramatic. But several important factors complicate the comparison.

The Trials Studied Different Populations

The retatrutide phase 2 trial enrolled U.S. adults with obesity, with participants generally having a higher average baseline BMI.

The mazdutide DREAMS-1 population consisted of Chinese adults with obesity and a lower average baseline BMI.

Starting BMI can influence the amount and percentage of weight a person loses during an obesity trial.

Phase 2 and Phase 3 Are Not the Same

Retatrutide's approximately 24% figure came from phase 2 research.

Mazdutide's figures came from phase 3 development.

Phase 2 trials are generally smaller and can involve more carefully selected participants. Results can therefore shift when a drug moves into larger, more diverse phase 3 populations.

That means it would be premature to say that retatrutide will definitely produce exactly 24% weight loss in a future broad population.

The Better Conclusion

The available evidence suggests that retatrutide has a highly potent weight-loss profile, while mazdutide also demonstrates substantial efficacy.

But the exact size of the difference cannot be established from these separate trials.

Why Does Retatrutide Include GIP?

GIP is one of the most interesting parts of the retatrutide equation.

Tirzepatide already demonstrated that combining GLP-1 and GIP activity can produce greater weight loss than GLP-1 receptor activation alone in clinical trials.

Retatrutide takes that concept and adds glucagon activity.

That creates a progression:

GLP-1 → GLP-1 + GIP → GLP-1 + GIP + glucagon

Clinical results broadly support the idea that combining these pathways can increase weight-loss efficacy.

The exact contribution of GIP remains an active area of research, however. Preclinical studies have produced differing conclusions about the precise role of GIP receptor signaling, so it would be an oversimplification to say that one receptor alone explains retatrutide's results.

Mazdutide vs Retatrutide: Side Effects

Both medications produce gastrointestinal adverse effects consistent with incretin-based therapies.

Reported effects include:

• Nausea

• Diarrhea

• Vomiting

• Reduced appetite

• Changes in gastrointestinal motility

These effects tend to become more noticeable during dose escalation.

Retatrutide's highest doses have been associated with relatively frequent gastrointestinal events in clinical research, which is unsurprising given its strong multi-receptor activity.

Mazdutide's adverse-event profile in clinical development has generally been consistent with the broader GLP-1 drug class.

Other Safety Considerations

Both drugs can affect heart rate and glucose metabolism. Hepatic outcomes have also been an area of interest because glucagon signaling influences liver metabolism.

However, neither medication currently has the enormous long-term cardiovascular outcomes database available for established drugs such as semaglutide.

That distinction is important: promising metabolic signals are not the same thing as decades of accumulated safety data.

Is Mazdutide Approved?

Yes, but approval is geographically limited.

Mazdutide received approval in China for obesity and is marketed there as Sineipasy.

Its regulatory position is therefore fundamentally different from retatrutide.

For patients elsewhere, approval and availability depend on local regulatory decisions. Being approved in one country does not automatically make a drug legal or available for routine treatment in another.

Is Retatrutide FDA Approved?

No.

Retatrutide remains an investigational medication in the United States while phase 3 studies continue.

That means it should not be treated as an FDA-approved weight-loss medication or as an established alternative to currently approved therapies.

For U.S. patients, legitimate treatment options currently include FDA-approved medications such as semaglutide and tirzepatide when prescribed for appropriate indications.

Why Is Mazdutide Primarily a China-Focused Product?

The difference is partly about business strategy rather than pharmacology.

1. Lilly Already Has Tirzepatide

Tirzepatide is Lilly's established GLP-1/GIP product in major markets.

Introducing another dual agonist into the same markets could create competition within Lilly's own portfolio.

Retatrutide, meanwhile, represents a more distinct next-generation triple-agonist strategy.

2. Innovent Has Greater China Rights

Lilly licensed development and commercialization rights for mazdutide in Greater China to Innovent.

That partnership created a pathway for development specifically focused on the Chinese market.

3. Regulatory Development Is Region-Specific

Clinical development programs are designed around the requirements of the regulatory agencies involved.

A drug developed primarily through a China-focused pathway cannot simply be assumed to qualify for approval in the United States without the necessary evidence and regulatory submissions.

4. Different Markets Have Different Treatment Needs

Obesity is not identical across populations. Patient characteristics, healthcare systems, prescribing practices, and regulatory requirements differ from country to country.

That makes regional portfolio strategies commercially and clinically important.

What Happens to Retatrutide Next?

Retatrutide is one of Lilly's most closely watched investigational obesity medicines.

Its phase 3 program is intended to answer several questions that phase 2 studies cannot fully resolve:

• How effective is it in a much larger population?

• How durable is the weight loss?

• What happens at longer treatment durations?

• How tolerable are the higher doses?

• What are the cardiovascular and metabolic safety implications?

• How does it compare with established obesity treatments?

Those results will ultimately determine whether its early promise translates into a successful regulatory application.

Is a Triple Agonist Actually Better Than a Dual Agonist?

Not necessarily for every patient.

The argument in favor of the triple-agonist strategy is obvious: people with severe or treatment-resistant obesity may benefit from even greater weight reduction.

But there are trade-offs.

The Case for Dual Agonists

Mazdutide illustrates a potentially simpler approach. A dual agonist can activate two complementary pathways without adding GIP signaling.

The additional weight loss from another receptor may not always justify additional gastrointestinal effects or other unknowns.

The Case for Triple Agonists

Retatrutide's early results suggest that combining all three pathways could push weight loss beyond what has been seen with many existing treatments.

For patients who need substantial weight reduction, even a few additional percentage points can represent a meaningful difference.

Ultimately, the question is not simply "Which drug produces the largest number?"

It's "Which treatment provides the best balance of efficacy, tolerability, safety, and long-term sustainability for a particular patient?"

What About Retatrutide vs Tirzepatide?

This is an especially important comparison because tirzepatide is already an established therapy.

Tirzepatide activates GLP-1 and GIP receptors, while retatrutide adds glucagon activity.

Early retatrutide data suggest greater weight-loss potential than what has historically been seen with many existing therapies, but cross-trial comparisons should be interpreted cautiously.

A direct, appropriately designed head-to-head trial is far more informative than comparing percentages from separate studies.

What About Research-Peptide Versions?

This is where caution is essential.

Retatrutide and other investigational molecules may appear online as so-called "research" products. These products should not be confused with pharmaceutical formulations studied in regulated clinical trials.

A vial sold online may have uncertain:

• Identity

• Concentration

• Purity

• Sterility

• Storage history

• Manufacturing quality

The fact that a chemical has the same name as an investigational drug does not mean it is equivalent to the pharmaceutical product used in clinical research.

Using an unapproved injectable product outside a legitimate clinical or medical setting introduces risks that clinical-trial evidence cannot answer.

Which Drug Is Relevant Depending on Where You Live?

If You're in the United States

Neither mazdutide nor retatrutide should be considered an FDA-approved treatment option.

The more relevant approved therapies include established medications such as semaglutide and tirzepatide, depending on your medical history and indication.

If You're in China

Mazdutide is the relevant approved option of the two, subject to a clinician determining that treatment is appropriate.

If You're Watching the Obesity Drug Pipeline

Retatrutide is the molecule to watch most closely for potential future U.S. availability because its development is directly targeting major international markets.

Mazdutide, meanwhile, represents an important example of how the same pharmaceutical portfolio can be developed differently across regions.

The Bottom Line

Mazdutide and retatrutide share an important idea: glucagon signaling may enhance the metabolic effects of GLP-1-based obesity treatment.

Mazdutide combines GLP-1 and glucagon activity. Retatrutide adds GIP, creating a triple-agonist approach.

Early data make retatrutide look particularly powerful, with phase 2 results approaching 24% average weight loss at the highest studied dose. Mazdutide has also demonstrated meaningful weight reduction in phase 3 research, including approximately 14.4% at 9 mg over 48 weeks.

But these percentages should not be treated as a direct head-to-head contest. Different populations, baseline BMIs, trial phases, sample sizes, and study designs make cross-trial comparisons imperfect.

For now, the regulatory distinction is much clearer: mazdutide is approved for obesity in China, while retatrutide remains investigational.

The next major milestone will be retatrutide's phase 3 data. Those results will show whether the impressive early weight-loss signal can hold up in larger populations while maintaining an acceptable safety and tolerability profile.

For patients, the smartest approach is to focus less on which molecule has the most impressive headline number and more on medications that are approved, clinically supported, appropriately prescribed, and suitable for their individual health needs.

Sources

1. Jastreboff AM et al. Triple-Hormone Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023.

2. Ji L et al. Mazdutide for chronic weight management in Chinese adults (DREAMS-1). 2024-2025.

3. Eli Lilly. Annual Report Pipeline Disclosure. 2024.

4. Innovent Biologics. NMPA Approval for Sineipasy. 2025.

5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.

6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.

7. le Roux CW et al. Survodutide for obesity (phase 2). Lancet. 2024.

8. Coskun T et al. LY3437943 (retatrutide), a novel triple agonist: preclinical pharmacology. Cell Metabolism. 2022.

9. Eli Lilly. TRIUMPH Phase 3 Program Disclosures. 2024-2025.

10. National Medical Products Administration (China). Approval Documents. 2025.

11. Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.